Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TRC253 |
| Synonyms | |
| Therapy Description |
TRC253 binds androgen receptor (AR), including wild-type AR and some mutant versions, resulting in decreased receptor activation and downstream signaling, and potentially leading to decreased growth of AR-expressing tumor cells (PMID: 30462924). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TRC253 | JNJ-63576253|TRC-253|TRC 253 | Hormone - Anti-androgens 57 | TRC253 binds androgen receptor (AR), including wild-type AR and some mutant versions, resulting in decreased receptor activation and downstream signaling, and potentially leading to decreased growth of AR-expressing tumor cells (PMID: 30462924). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02987829 | Phase Ib/II | TRC253 | A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | Completed | USA | 0 |